organovo.com - רווח נקי למניה ב-12 החודשים האחרונים VIVS

VivoSim Labs Inc (VIVS) business is characterized by low cyclicality due to stable R&D investments from pharma behemoths. The EPS ttm YoY trend visualizes market imbalances, where the value of -343.00 reflects this status. VivoSim Labs Inc (VIVS) is modernizing drug development by creating functional organ models. Process robotization is driven by automated bioprinters that precisely print living tissues for testing.
Organovo Holdings - פילוחים אנליטיים ומדדי מפתח (VIVS)

Investors must identify the fundamental drivers of asset resilience through the dynamics of per-share profit. This metric is calculated as the percentage change in earnings per share over the last 12 months relative to the same period last year. The current EPS YoY shift for the last 12 months on the GURU.Markets platform visualizes the business capitalization rates. Growth in this indicator confirms the effective monetization of 3D bioprinting and the licensing of developments by VivoSim Labs Inc (VIVS). The stable trend of the line proves the demand for organ models in pharmaceutical testing.